CA2659874C — Methods for the treatment of radiation proctosigmoiditis
Assigned to Salix Pharmaceuticals Inc · Expires 2016-10-11 · 10y expired
What this patent protects
This invention relates to the use of a pharmaceutically effective amount of rifaximin in treating enteritis caused by an abdominopelvic therapy in a subject in need thereof as well as the use of a pharmaceutically effective amount of rifaximin before, during or after undergoing r…
USPTO Abstract
This invention relates to the use of a pharmaceutically effective amount of rifaximin in treating enteritis caused by an abdominopelvic therapy in a subject in need thereof as well as the use of a pharmaceutically effective amount of rifaximin before, during or after undergoing radiation therapy for protecting a subject against radiation induced enteritis, radiation induced injury to the mucosa of the colon or radiation induced colorectal inflammation. It also relates to the use of a pharmaceutically effective amount of rifaximin in treating enteritis in a subject or monitoring the progress of a subject being treated for enteritis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.